RefleXion Podcast

Rose Higgins, chief executive officer at HealthMyne, sits down with Sam to discuss the role radiomics is playing in cancer care. Our biology-guided radiotherapy will generate a plethora of new data that will one day become part of the data fabric to help us understand what is happening at both the molecular and biological level. This podcast dives into how radiomics can provide insights to better inform treatment decisions and what the future may hold.

RefleXion's Chief Business Officer, Thorsten Melcher Ph.D., and Chris Behrenbruch Ph.D, founder and CEO of Telix Pharmaceuticals, explore how holistic treatment strategies for metastatic cancer patients interact with the world of commerce. What is the role of radiopharmacueticals in the radiotherapy delivery? What influence does the design of clinical trials have on market authorization? Why would a company deliberately integrate with an existing therapy rather than replace it? Find out in this forward-looking discussion. Speakers: Thorsten Melcher Ph.D. - CBO, RefleXion Chris Behrenbruch Ph.D, - Founder and CEO, Telix Pharmaceuticals For more information, please visit https://reflexion.com

Thorsten Melcher Ph.D., CBO at RefleXion, and Dr. Giovanni Selvaggi, CEO and CMO at Xcovery, discuss advances in two key areas that could mean a longer life for more Stage 4 patients. The watchwords are customization and personalization. The finding that the customized pairing of two therapies, used in combination, versus in a sequence, creates a synergistic effect, is coupled with the realization every patient's cancer is personalized to their unique system. Developing a plan that includes a patient assessment, multiple treatment options, and how best to combine them, is a promising new direction. Speakers: Thorsten Melcher Ph.D. - CBO, RefleXion Giovanni Selvaggi, M.D. - CEO & CMO, Xcovery For more information, please visit https://reflexion.com

Dr. Arya Amini, faculty radiation oncologist at City of Hope Cancer Center, joins Sean to discuss the promise and complexity of envelope-pushing therapies and current state of clinical research. Dr. Amini's fascination with cancer took hold in high school, continued through medical school, and ultimately has brought him to the field of radiation oncology – allowing him to focus on both patients and research. Hear how the industry has shifted from IMRT to SBRT and now a focus on both local and systemic therapies to treat metastatic disease. This forward-thinking conversation covers a lot of ground and you don't want to miss it. Speakers: Arya Amini, M.D. - Assistant Clinical Professor and Chief of Thoracic Radiotherapy, Department of Radiation Oncology for City of Hope Comprehensive Cancer Center Sean Shirvani, M.D. - Chief Medical Officer, RefleXion For more information, please visit https://reflexion.com

Sean is joined by Dr. George Simon, Executive Director of Moffitt Cancer Center-AdventHealth joint Clinical Research Unit, to identify key crossroads in the treatment landscape for metastatic cancer patients. If the distinctions among systemic, local, and immunotherapies are a bit baffling to you they won't be for long. Dr. Simon details these and other approaches such as checkpoint inhibitors, available in the just the last five years or so. The pace of change is exhilarating for physicians and patients. Though there is still much to learn, there is also much to celebrate. Speakers: George Simon, M.D. - Executive Medical Director and Department Chair, Moffitt Cancer Center-AdventHealth joint Clinical Research Unit Sean Shirvani, M.D. - Chief Medical Officer, RefleXion For more information, please visit https://reflexion.com